Celltrion Healthcare | Sustainability Performance

https://www.celltrionhealthcare.com/

Distributes biopharmaceutical products to global healthcare providers and commercial partners.

1999

South Korea

51 - 200 employees

Pharmaceuticals

$1B - 10B in revenue

$100M - 500M in profitability

Submit or report inaccurate data Download Company Insights

Sustainability Ranking & Industry Benchmark

#9172

Overall

#108

in South Korea

#213

in Pharmaceuticals

Sustainability Maturity

Sustainability Intent

Available in
Scale package

Access

Industry Rank

215 out of 311

Overview

Environmental

Carbon emissionsEnergy consumptionClimate risk

Social

Diversity and InclusionPay GapsHealth and SafetyExternalities

Governance

TargetsSDG ImpactESG scores and Exclusions

Financial Data

Business performanceCapital & innovationAnalyst projections

View similiar companies

Seegene

South Korea, Health Care, Biotechnology

Suheung

South Korea, Health Care, Pharmaceuticals

Shinpoong Pharm

South Korea, Health Care, Pharmaceuticals

Female employees

55% 2024

Leading

Externalities

1.9M $, 2022

Critical

Market cap

11.8T $, 2024▼22% YoY

Revenue

2.0T $, 2022▼8.5% YoY

R&D intensity

0.9% 2022

Controversy level

Very Low

Low

Noticeable

High

Severe

Download Controversy Analysis

Celltrion Healthcare Inc (post2023 CelltrionCelltrion Healthcare merger creating consolidated Celltrion), Korean major biosimilar manufacturer (Remsima/Inflectra infliximab, Truxima rituximab, Yuflyma adalimumab), has faced multiple international class actions over alleged inadequate disclosure of US/European biosimilar customer demand normalization, plus the historic 2023 Korean FSC merger integration challenges affecting Korean institutional shareholders.

KPI	Metric	Year
	2018	2019	2020	2021	2022	Benchmark
*******	*******	-	-	*******	*******	*******	*******

Land use

Reveal data for 2 credits

KPI	Metric	Year
		2018	2019	2020	2021	2022	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Diversity & inclusion

Reveal data for 3 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Pay gap breakdown

Reveal data for 1 credit

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	-	-	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	-	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	-	-	-	*******	*******	*******

KPI	Metric	Year
	2018	2019	2020	2021	2022	Benchmark
*******	*******	-	*******	-	-	*******	*******

Externalities

Reveal data for 1 credit

KPI	Metric	Year
		2018	2019	2020	2021	2022	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

SDG impact (historical)

Reveal data for 5 credits

KPI	Metric	Year
		2017	2018	2019	2020	2021	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Reporting

Sustainability Report

Available

Not committed to key sustainability initiatives

Sustainability employees

Total sustainability employees

Available in
Scale package

Access

Controversy level

Very Low

Low

Noticeable

High

Severe

Download Controversy Analysis

Celltrion Healthcare Inc (post2023 CelltrionCelltrion Healthcare merger creating consolidated Celltrion), Korean major biosimilar manufacturer (Remsima/Inflectra infliximab, Truxima rituximab, Yuflyma adalimumab), has faced multiple international class actions over alleged inadequate disclosure of US/European biosimilar customer demand normalization, plus the historic 2023 Korean FSC merger integration challenges affecting Korean institutional shareholders.

Celltrion Healthcare | Sustainability Performance

Sustainability Ranking & Industry Benchmark

Sustainability Maturity

Sustainability Intent

Available in Scale package

View similiar companies

Renewable energy

Female employees

Controversy level

Carbon emissions breakdown

Climate risk

Land use

Diversity & inclusion

Pay gap breakdown

Health & safety

Externalities

Revenue & EBITDA

Margin trends

R&D intensity

Return on invested capital

Analyst revenue estimates & actuals

Environmental policy coverage

Overall score

Environment

Social

Governance

Exclusion screening

SDG impact

SDG impact (historical)

Reporting

Sustainability employees

Available in Scale package

Celltrion Healthcare | Sustainability Performance

Sustainability Ranking & Industry Benchmark

Sustainability Maturity

Sustainability Intent

Available in Scale package

View similiar companies

Renewable energy

Female employees

Controversy level

Carbon emissions breakdown

Climate risk

Land use

Diversity & inclusion

Pay gap breakdown

Health & safety

Externalities

Revenue & EBITDA

Margin trends

R&D intensity

Return on invested capital

Analyst revenue estimates & actuals

Environmental policy coverage

Overall score

Environment

Social

Governance

Exclusion screening

SDG impact

SDG impact (historical)

Reporting

Sustainability employees

Available in Scale package

Available in
Scale package

Available in
Scale package

Available in
Scale package

Available in
Scale package